Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
106M
-
Number of holders
-
23
-
Total 13F shares, excl. options
-
2.18M
-
Shares change
-
-185K
-
Total reported value, excl. options
-
$4.41M
-
Value change
-
-$489K
-
Put/Call ratio
-
0.12
-
Number of buys
-
8
-
Number of sells
-
-8
-
Price
-
$2.02
Significant Holders of SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) as of Q3 2022
33 filings reported holding SLS - SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share as of Q3 2022.
SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) has 23 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.18M shares
of 106M outstanding shares and own 2.06% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (830K shares), Empery Asset Management, LP (308K shares), BlackRock Inc. (256K shares), GEODE CAPITAL MANAGEMENT, LLC (145K shares), Equitable Holdings, Inc. (110K shares), CITADEL ADVISORS LLC (108K shares), HIGHBRIDGE CAPITAL MANAGEMENT LLC (100K shares), STATE STREET CORP (58.2K shares), TWO SIGMA INVESTMENTS, LP (53.7K shares), and MORGAN STANLEY (53.4K shares).
This table shows the top 23 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.